LA
VRTX icon

LVW Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

LVW Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$446K Sell
898
-190
-17% -$84.2K 0.04% 254
2026
Q1 		$486K Sell
1,088
-386
-26% -$180K 0.05% 219
2025
Q4 		$668K Buy
1,474
+503
+52% +$217K 0.07% 143
2025
Q3 		$380K Buy
971
+158
+19% +$66K 0.04% 236
2025
Q2 		$362K Buy
813
+19
+2% +$8.76K 0.04% 240
2025
Q1 		$385K Buy
794
+28
+4% +$13K 0.05% 210
2024
Q4 		$308K Sell
766
-26
-3% -$12.1K 0.04% 246
2024
Q3 		$368K Buy
792
+50
+7% +$24K 0.05% 214
2024
Q2 		$348K Buy
742
+129
+21% +$56K 0.05% 211
2024
Q1 		$256K Buy
+613
New +$259K 0.04% 249

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

LVW Advisors's VRTX Position: Q2 2026 in Review

LVW Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 17% in Q2 2026, selling an estimated $84.2K and leaving 898 shares worth $446K. The position accounts for 0.04% of the portfolio, ranked #254.

LVW Advisors first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $668K in Q4 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • LVW Advisors held 898 shares of Vertex Pharmaceuticals worth $446K as of Q2 2026.
  • LVW Advisors sold 190 Vertex Pharmaceuticals shares in Q2 2026, an estimated $84.2K.
  • Vertex Pharmaceuticals made up 0.04% of LVW Advisors's portfolio in Q2 2026, its #254 holding.
  • LVW Advisors first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • LVW Advisors's Vertex Pharmaceuticals position peaked at $668K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on LVW Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.